BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 33933558)

  • 21. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The SSX family of cancer-testis antigens as target proteins for tumor therapy.
    Smith HA; McNeel DG
    Clin Dev Immunol; 2010; 2010():150591. PubMed ID: 20981248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CAR-Ts: new perspectives in cancer therapy.
    Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
    FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy.
    Bodey B
    Expert Opin Biol Ther; 2002 Aug; 2(6):577-84. PubMed ID: 12171503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
    Crupi MJF; Bell JC; Singaravelu R
    Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
    Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
    Front Immunol; 2018; 9():3062. PubMed ID: 30740109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
    Lei X; Lei Y; Li JK; Du WX; Li RG; Yang J; Li J; Li F; Tan HB
    Cancer Lett; 2020 Feb; 470():126-133. PubMed ID: 31730903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward.
    Jafarzadeh L; Masoumi E; Fallah-Mehrjardi K; Mirzaei HR; Hadjati J
    Front Immunol; 2020; 11():702. PubMed ID: 32391013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogenic cancer/testis antigens: prime candidates for immunotherapy.
    Gjerstorff MF; Andersen MH; Ditzel HJ
    Oncotarget; 2015 Jun; 6(18):15772-87. PubMed ID: 26158218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
    Ott PA; Dotti G; Yee C; Goff SL
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAR T cells: continuation in a revolution of immunotherapy.
    Singh AK; McGuirk JP
    Lancet Oncol; 2020 Mar; 21(3):e168-e178. PubMed ID: 32135120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer.
    Hikmet F; Rassy M; Backman M; Méar L; Mattsson JSM; Djureinovic D; Botling J; Brunnström H; Micke P; Lindskog C
    Mol Oncol; 2023 Dec; 17(12):2603-2617. PubMed ID: 37341056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy for glioma: from illusion to realistic prospects?
    Dietrich PY; Dutoit V; Walker PR
    Am Soc Clin Oncol Educ Book; 2014; ():51-9. PubMed ID: 24857060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of Cancer-Testis Antigens in Pediatric Cancers.
    Ghafouri-Fard S
    Asian Pac J Cancer Prev; 2015; 16(13):5149-52. PubMed ID: 26225644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The therapeutic potential value of Cancer-testis antigens in immunotherapy of gastric cancer.
    Alsadat Mahmoudian R; Amirhosein M; Mahmoudian P; Fardi Golyan F; Mokhlessi L; Maftooh M; Khazaei M; Nassiri M; Mahdi Hassanian S; Ghayour-Mobarhan M; Ferns GA; Shahidsales S; Avan A
    Gene; 2023 Feb; 853():147082. PubMed ID: 36464170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.